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Germline loss- and gain-of-function mutations of G-protein
-11 (G11), which couples the calcium-sensing receptor
(CaSR) to intracellular calcium (Ca2i) signaling, lead to familial
hypocalciuric hypercalcemia type 2 (FHH2) and autosomal
dominant hypocalcemia type 2 (ADH2), respectively, whereas
somatic G11 mutations mediate uveal melanoma development
by constitutively up-regulatingMAPK signaling. Cinacalcet and
NPS-2143 are allosteric CaSR activators and inactivators,
respectively, that ameliorate signaling disturbances associated
with CaSR mutations, but their potential to modulate abnor-
malities of thedownstreamG11 protein is unknown.This study
investigated whether cinacalcet and NPS-2143 may rectify
Ca2i alterations associated with FHH2- and ADH2-causing
G11 mutations, and evaluated the influence of germline gain-
of-function G11 mutations on MAPK signaling by measuring
ERK phosphorylation, and assessed the effect of NPS-2143 on a
uveal melanoma G11 mutant. WT and mutant G11 proteins
causing FHH2, ADH2 or uveal melanoma were transfected in
CaSR-expressing HEK293 cells, and Ca2i and ERK phosphory-
lation responses measured by flow-cytometry and Alphascreen
immunoassay following exposure to extracellular Ca2 (Ca2o)
and allosteric modulators. Cinacalcet and NPS-2143 rectified
the Ca2i responses of FHH2- and ADH2-associated G11 loss-
and gain-of-function mutations, respectively. ADH2-causing
G11mutationsweredemonstratednot tobe constitutively acti-
vating and induced ERK phosphorylation following Ca2o stim-
ulation only. The increased ERK phosphorylation associated
with ADH2 and uveal melanomamutants was rectified by NPS-
2143. These findings demonstrate that CaSR-targeted com-
pounds can rectify signaling disturbances caused by germline
and somatic G11mutations, which respectively lead to calcium
disorders and tumorigenesis; and that ADH2-causing G11
mutations induce non-constitutive alterations in MAPK
signaling.
Guanine nucleotide-binding protein (G-protein)4 -11
(G11) is a major intracellular signaling partner of the cell-sur-
face G-protein-coupled calcium (Ca2)-sensing receptor
(CaSR), which plays a pivotal role in the parathyroid and renal
regulation of extracellular Ca2 (Ca2o) concentrations (1, 2).
G11 belongs to the Gq/11 class of G-proteins that enhance
phospholipase C activity (3), thereby leading to an accumula-
tion of inositol 1,4,5-trisphosphate and rapid increase in intra-
cellular Ca2 (Ca2i) concentrations (2, 4). These signal trans-
duction events allow the CaSR to respond to small fluctuations
in the prevailing Ca2o concentration ([Ca2]o) by inducing
alterations in parathyroid hormone (PTH) secretion and uri-
nary Ca2 excretion (5).
The identification of germline heterozygous loss- and gain-
of-functionmutations ofG11, which is encoded by theGNA11
gene on chromosome 19p13.3, that lead to forms of familial
hypocalciuric hypercalcemia (FHH) or autosomal dominant
hypocalcemia (ADH), respectively, has demonstrated the
importance of this G-protein subunit in Ca2o homeostasis (1,
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6, 7). FHH is a genetically heterogeneous disorder that is inher-
ited as an autosomal dominant condition, which is character-
ized by lifelong elevations of serum Ca2 concentrations in
association with normal or mildly raised serum PTH levels and
low urinary Ca2 excretion (8). FHH is considered to represent
a benign disorder, however some patients may develop symp-
tomatic hypercalcemia, pancreatitis, or chondrocalcinosis (8).
FHH type 1 (FHH1, OMIM #145980) is caused by loss-of-func-
tion mutations of the CASR gene (9), and FHH type 2 (FHH2,
OMIM#145981) is caused by loss-of-function G11 mutations,
which comprise a L135Q missense substitution and in-frame
isoleucine deletion at codon 199 or 200 (I199/200del) that
impair CaSR signal transduction and were identified in two
unrelated probands and families (1). ADH is also genetically
heterogeneous and caused by germline gain-of-function muta-
tions of the CASR and GNA11 genes, which lead to ADH types
1 (ADH1, OMIM #601198) and 2 (ADH2, OMIM #615361),
respectively (1, 6–10). Approximately 50% of ADH patients
develop hypocalcemic symptoms such as paraesthesia, carpo-
pedal spasms, and seizures, and 35% of patients harbor
ectopic calcifications within the kidneys or basal ganglia (1, 6, 7,
10). In contrast to germline gain-of-function G11 mutations,
which affect Ca2o homeostasis, somatic gain-of-function
G11 mutations have been reported to lead to uveal melanoma,
which is a primary intraocular tumor, by inducing constitutive
up-regulation of proliferative signaling involving ERK, which is
a component of the MAPK signaling pathway (11).
Compounds that selectively bind to the CaSR and allosteri-
cally modulate the function of this family C G-protein-coupled
receptor (GPCR) represent a potential targeted therapy for
patients with symptomatic forms of FHH and ADH. Indeed,
cinacalcet, which is a licensed CaSR positive allosteric modula-
tor, has been used effectively in FHH1 patients to manage
symptomatic hypercalcemia and recurrent pancreatitis (12,
13). Furthermore, negative allosteric CaSR modulators, known
as calcilytics, have been demonstrated to ameliorate hypocalce-
mia in mouse models of ADH1 (14, 15). The objective of this
study was to undertake in vitro studies to determine whether
allosteric modulators targeted to the CaSR may also rectify the
loss- and gain-of-function associated with FHH2- and ADH2-
causing germline G11mutations, respectively, and the up-reg-
ulation of ERK phosphorylation caused by a uveal melanoma-
associated somatic G11 mutation. In addition, this study
evaluated whether germline ADH2-causing gain-of-function
G11 mutations may constitutively activate MAPK signaling
and thus pose a risk for the development of uveal melanomas.
Experimental Procedures
Cell Culture and Transfection—Functional studies of mutant
G11 proteins were performed in HEK293 cells that stably
expressed the CaSR (HEK-CaSR) (1, 16, 17). HEK293 cells
endogenously express G11, and co-expression of mutant G11
proteins approximately represented the heterozygous state in
FHH2 and ADH2 patients (1). The HEK-CaSR cell line was
cultured in high-glucose DMEM (Invitrogen) supplemented
with 10% fetal bovine serum (FBS) and 1% geneticin, as
described (1, 16, 17). A high level of CaSR expression in these
cells was confirmed by Western blot analysis using a mouse
monoclonal antibody to human CaSR (ADD; Abcam,
ab19347, 1:1,000) (1, 16). WT and mutant GNA11-pBI-
CMV2 constructs were transiently transfected into HEK-
CaSR cells using Lipofectamine 2000 (1, 16, 17). The bidirec-
tional pBI-CMV2 cloning vector was used as it facilitated the
co-expression of G11 and GFP (1, 16, 18). Expression ofWT
and mutant G11 proteins were determined by Western blot
analysis using a mouse monoclonal anti-G11 antibody (San-
taCruz Biotechnology, sc-390382, 1:750), and the membrane
was re-probed with a polyclonal rabbit anti--tubulin anti-
body (Abcam, ab15246, 1:1000) as a loading control. Suc-
cessful transfection was also confirmed by visualizing GFP
fluorescence using an Eclipse E400 fluorescence microscope
with a Y-FL Epifluorescence attachment and a triband 4,6-
diamidino-2-phenylindole-FITC-Rhodamine filter, and
images captured using a DXM1200C digital camera and NIS-
Elements software (Nikon) (1, 16, 17).
Studies involving siRNA knockdown of endogenous G11
were undertaken in HEK293 cells that stably expressed WT or
mutant G11 proteins (HEK-G11). The HEK-G11 cells were
generated using HEK293 T-Rex-Flp-in stable cell lines (Life
Technologies), as reported (19). WT and mutant GNA11 con-
structs were cloned into the pcDNA5/FLP recombination tar-
get (FRT) expression vector (Life Technologies), and silent
mutations introduced to render the constructs resistant to
GNA11-targeted siRNA, thereby allowing investigation of the
mutant G11 protein in the absence of endogenous WT G11.
GNA11 constructs were transiently transfected into T-Rex-
Flp-in cells, and those cells expressing theG11 protein selected
by culturing cells in medium containing Hygromycin (Gibco).
The presence of the G11 protein and its resistance to siRNA
was confirmed by Western blot analysis. Forty-eight hours
prior to measuring Ca2i responses, HEK-G11 cells were
transiently transfected with the reported pEGFP-CaSR con-
struct (9) and three different commercially available
GNA11-targeted siRNA constructs (Trilencer-27 siRNA kit,
catalogue number SR301839, Origene) or a commercially
available scrambled siRNA (Trilencer-27 universal scram-
bled negative control siRNA duplex, catalogue number
SR30004, Origene), and successful transfection confirmed
by fluorescence microscopy, as described for pBI-CMV2-
expressing HEK-CaSR cells (1, 16, 17).
Measurement of Ca2i Responses—The effect of allosteric
CaSRmodulators on cells expressingWT or mutant G11 pro-
teins was assessed by a flow cytometry-based Ca2i assay, as
reported (1, 16, 17). In brief, 48 h after transfection, the cells
were harvested, washed in Ca2- and magnesium (Mg2)-free
Hank’s balanced salt solution (HBSS) (Invitrogen), and loaded
with 1g/ml indo-1-acetoxymethylester (Indo-1-AM) (Molec-
ular Probes) for 1 h at 37 °C (1, 16, 17). Transfected cells were
incubated with either a 20% aqueous solution of 2-hydroxypro-
pyl--cyclodextrin (Sigma) (vehicle), or positive or negative
CaSR allosteric modulators, known as cinacalcet or NPS-2143,
respectively, at concentrations ranging from 10–40 nM for 1 h
(15). Flow cytometry was performed with a Beckman Coulter
MoFlo XDP equipped with JDSUY Xcyte UV Laser and a
Coherent Sapphire 488 Laser using a 550LP dichroic mirror
and 580/30 bandpass filter (17). Single cells were isolated and
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stimulated by sequentially addingCa2 to theCa2- andMg2-
free HBSS to increase the [Ca2]o in a stepwise manner from
0–15mM. The range of [Ca2]o used to activate CaSR signaling
inHEK293 cells was not representative of physiological levels of
serum ionized calcium, which are homeostatically maintained
between 1.1–1.3 mM (20), but use of these Ca2o concentra-
tions in vitro allowed a comprehensive assessment of CaSR sig-
naling responses, which included threshold responses (1–1.5
mM [Ca2]o), half-maximal (EC50) responses (2–4 mM
[Ca2]o), and near-maximal responses (10 mM), as reported
(21). The baseline fluorescence ratio was measured for 2 min,
the fluorescence ratio compared with the time was recorded,
and data were collected for 2 min at each [Ca2]o, as described
(1, 16, 17). Cytomation Summit softwarewas used to determine
the peakmean fluorescence ratio of the transient response after
each individual stimulus, which was expressed as a percentage
normalized response (1, 16, 17). Concentration-response
curves were generated using a 4-parameter non-linear regres-
sion curve-fit model (GraphPad Prism) to calculate the half-
maximal (EC50) and area under the curve (AUC) mean  S.E.
responses for each separate experiment (17).
Measurement of ERK Phosphorylation—HEK-CaSR cells,
transfected with WT or mutant G11 proteins for 24 h, were
seeded in 48-well plates and cultured overnight in high glucose
DMEM containing 10% FBS, prior to being incubated for 4 h
with serum-free DMEM containing 0.5 mM Ca2, 25 mM
HEPES buffer with or without cinacalcet or NPS-2143 at
10–500 nM concentrations. Cells were stimulated for 4 min
with pre-warmed serum-free DMEM that contained Ca2 con-
centrations ranging from 0.5–10 mM, as reported (22), and
lysed in Surefire lysis buffer. Alphascreen Surefire ERK phos-
phorylation assays were performed on whole cell lysates, as
reported (23), and the fluorescence signal measured using a
PHERAStar FS microplate reader (BMG Labtech) (23). ERK
phosphorylation responsesmeasured at each [Ca2]owere nor-
malized to the mean responses of WT expressing cells and
expressed as a fold-change of responses obtained at basal (0.5
mM) [Ca2]o.
Statistical Analysis—The Ca2i and ERK phosphorylation
responses of cells expressingWTormutantG11 proteinswere
compared from a minimum of four experiments using the
F-test and Mann-Whitney U test, respectively (1). All analyses
were undertaken using GraphPad Prism (GraphPad), and are
presented as mean  S.E. A value of p  0.05 was considered
significant for all analyses.
Results
Effect of Cinacalcet on the Ca2i Responses of FHH2-associ-
ated G11 Mutations—The FHH2-associated L135Q and I199/
200del G11 mutations have been reported to impair the sensi-
tivity of CaSR-expressing cells to Ca2o (1), and we
hypothesized that cinacalcet-mediated allosteric activation of
theCaSRwould ameliorate the loss-of-function associatedwith
germlinemutations of G11, thereby rectifying the signal trans-
duction abnormalities in cells expressing these FHH2-associ-
ated mutant G11 proteins. To investigate this hypothesis, WT
or mutant GNA11-pBI-CMV2 constructs were transiently
transfected in HEK-CaSR cells and the effect of cinacalcet on
the responses of Ca2i concentrations ([Ca2]i) to alterations
in [Ca2]o was assessed. Expression of the CaSR and G11 was
confirmed by fluorescence microscopy and/or Western blot
analysis of whole-cell lysates (Fig. 1,A and B). CaSR expression,
which was normalized by comparison to -tubulin expression,
did not differ between cells transfected with WT or FHH2-
associatedmutantGNA11-pBI-CMV2 vectors when compared
with cells transfected with empty vector, whereas the expres-
sion ofG11 was greater in cells transfectedwithWTormutant
constructs (Fig. 1B). HEK-CaSR cells transiently transfected
with WT or mutant G11 proteins were exposed to varying
[Ca2]o, andmeasurement of [Ca2]i responses by flow cytom-
etry revealed the FHH2-associated Gln-135 and del199/200
G11 mutants to result in a rightward shift of the concentra-
tion-response curves (Fig. 1C) with a significant reduction in
AUC values and increases in EC50 values (Gln-135  3.54 
0.07 mM, del199/200  3.49  0.04 mM) compared with WT
G11 (2.67 0.03mM; p 0.0001) (Fig. 1,D and E), as reported
(1). A dose-titration of cinacalcet in cells expressing the Gln-
135G11mutant revealed this calcimimetic to act in a dose-de-
pendent manner, with 10 and 20 nM drug concentrations sig-
nificantly (p  0.0001) reducing the Gln-135 mutant EC50
values to 2.75 0.03 and 2.61 0.09mM, respectively (Fig. 1E).
Indeed, 10 nM of cinacalcet induced a leftward shift of the
mutant concentration-response curve, so that this was indistin-
guishable from that ofWT-expressing cells (Fig. 1F). The addi-
tion of 10 and 20 nM cinacalcet lowered the EC50 values of cells
expressing the del199/200 G11 mutant (Fig. 1E). However,
despite the del199/200 mutant having an almost identical EC50
value to the Gln-135 G11 mutant protein, these cinacalcet
doseswere insufficient to rectify the loss-of-function associated
with the del199/200G11mutant (Fig. 1E). Subsequently, when
cinacalcet was added at a 40 nM concentration to cells express-
ing the del199/200 G11 mutant, this lowered the EC50 value to
2.68  0.04 mM (Fig. 1E), so that the del199/200 mutant con-
centration-response curve overlapped with that of the WT
G11 protein (Fig. 1G).
Effect of NPS-2143 on the Ca2i Responses of ADH2-associ-
ated G11 Mutations—We previously reported the germline
R181Q and F341L G11 mutations to enhance the sensitivity of
CaSR-expressing cells to Ca2o (1), thereby giving rise to the
hypocalcemic disorder of ADH2. To determine whether allos-
teric inhibition of the CaSR can rectify the gain-of-function
associatedwithADH2-causingG11mutations,WTorADH2-
associatedmutantGNA11-pBI-CMV2 vectors were transiently
transfected into HEK-CaSR cells, and the responses of [Ca2]i
to alterations in [Ca2]o assayed. Expression of the CaSR and
G11 was demonstrated by fluorescence microscopy and/or
Western blot analysis (Fig. 2, A and B). Western blot analysis
confirmed an increase in the expression of G11 in cells trans-
fected with WT or ADH2-associated mutant proteins, when
compared with cells transfected with empty vector alone (Fig.
2B). An assessment of the Ca2i responses of HEK-CaSR cells
transiently transfected with WT or ADH2-associated mutant
G11 proteins following stimulation with [Ca2]o, demon-
strated cells expressing the Gln-181 or Leu-341 mutants to
induce a leftward shift of the concentration-response curves
(Fig. 2C) with a significant increase in AUC values and reduc-
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FIGURE 1. Effect of cinacalcet on the Ca2i responses of FHH2-associated G11 mutations. A, fluorescence microscopy of HEK293 cells stably expressing CaSR
(HEK-CaSR) and transiently transfectedwithWTor FHH2-associated (Gln-135 anddel199/200)mutant (m)GNA11-pBI-CMV2-GFP constructs, orwith vector only. GFP
expression in these cells indicates successful transfection andexpressionby these constructs. Bar indicates 20m. B,Westernblot analysis ofwhole cell lysates using
antibodies toCaSR,-tubulin, andG11. Transient transfection ofWTor FHH2-associatedmutant constructs resulted in over-expressionofG11whennormalized to
-tubulin expression. C andD, Ca2i response to changes in [Ca
2]oofHEK-CaSR cells transfectedwithWTor FHH2-associatedG11mutants. TheCa
2
i responses to
changes in [Ca2]o are expressed as a percentage of the maximum normalized responses and shown as the mean S.E. of 6–16 assays from 2–4 independent
transfections. The FHH2-associated G11 mutants (Gln-135 and del199/200) led to a rightwards shift of the concentration-response curves (blue) with significantly
reduced AUC values (blue bars) when compared with WT G11 (in C, black; and in D, open bar), which harbors Leu and Ile residues at codons 135 and 199/200,
respectively.E, FHH2-associatedGln-135anddel199/200mutants (bluebars)areassociatedwithsignificantly increasedEC50valuescomparedwithcellsexpressingWT
G11 (openbar). Theadditionof 10and20nMcinacalcet (Cin) decreased theEC50 valuesof cells expressingGln-135 tovalues thatwerenot significantlydifferent from
WT,whereas 40nMcinacalcetwas required to rectify the increasedEC50 valueof cells expressing thedel199/200mutant. FandG, additionofcinacalcetat10and40nM
concentrationsrectifiedtherightwardshift intheconcentration-responsecurvesoftheGln-135anddel199/200mutantG11proteins,respectively.*,p0.05;***,p0.0001.
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FIGURE 2. Effect of NPS-2143 on the Ca2i responses of ADH2-associated G11 mutations. A, fluorescence microscopy of HEK293 cells stably expressing
CaSR (HEK-CaSR) and transiently transfected with vector, WT, or ADH2-associated (Gln-181 and Leu-341) mutant (m) constructs. GFP expression in these cells
indicates successful transfection and expression by these constructs. Bar indicates 20 m. B, Western blot analysis of whole cell lysates using antibodies to
CaSR, -tubulin, and G11. Transient transfection of WT or ADH2-associated mutant constructs resulted in overexpression of G11 when normalized to
-tubulin expression. C and D, Ca2i response to changes in [Ca
2]o of HEK-CaSR cells transfected with WT or ADH2-associated G11 mutants. The Ca
2
i
responses to changes in [Ca2]o are expressed as a percentage of themaximumnormalized responses and shown as themean S.E. of 6–16 assays from 2–4
independent transfections. The ADH2-associated G11 mutants (Gln-181 and Leu-341) led to a leftwards shift of the concentration-response curves (red) with
significantly increased AUC values (red bars) when comparedwithWT G11 (in C, black; and inD, open bar), which harbors Arg and Phe residues at codons 181
and 341, respectively. E, ADH2-associated Gln-181 and Leu-341 mutants (red bars) are associated with significantly reduced EC50 values compared with cells
expressing WT G11 (open bar). The addition of 10 nM NPS-2143 (2143) increased the EC50 value of cells expressing the Gln-181 mutant so that this was not
significantly different from WT, whereas 30 nM of NPS-2143 was required to rectify the reduced EC50 value of cells expressing the Leu-341 mutant. F and G,
addition of NPS-2143 at 10 and 30 nM concentrations rectified the leftward shift in the concentration-response curves of theGln-181 and Leu-341mutant G11
proteins, respectively. *, p 0.05; **, p 0.01; ***, p 0.0001.
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tion in EC50 values of 2.38 0.08 and 2.29 0.07 mM, respec-
tively, compared with 2.57 0.03 mM for WT-expressing cells
(p  0.0001) (Fig. 2, D and E), as previously reported (1). The
additionofNPS-2143 tocells expressing theGln-181G11mutant
revealed a 10nMconcentrationof this calcilytic compound tonor-
malize the mutant EC50 value to 2.57 0.07 mM (Fig. 2E), so that
the concentration-response curve resembled that of WT G11
(Fig. 2F), whereas 20 nM NPS-2143 significantly increased the
mutant EC50 value to 2.72 0.12 mM when compared with WT
expressing cells (Fig. 2E). In contrast to these studies involving the
FIGURE 3.Effect of cinacalcet andNPS-2143on theCa2i responsesof FHH2- andADH2-associatedG11mutations following siRNAknockdownof endog-
enously expressedWTG11. A, Western blot analysis of untransfected HEK293 cells, which express endogenousWTG11 only, and have been treatedwith either
scrambledsiRNA,or threedifferentGNA11-targetedsiRNAs (siRNAs1–3), either aloneorall together (siRNAs123), andcomparedwithuntreatedHEK293cells.All
threeGNA11-targeted siRNAs, but not scrambled siRNA, reduced endogenousWT G11 expression. B, Western blot analysis showing combined effects of the three
GNA11-targetedsiRNAsonG11proteinexpression inHEK293cells transientlyexpressingWTG11proteinsand inHEK-G11 cells,which stablyexpressWTormutant
G11 proteins. Use of GNA11-targeted siRNAs reduced G11 expression in HEK293 cells, but not in HEK-G11 cells, which are resistant to GNA11-targeted siRNA. C,
fluorescence microscopy confirming transfection of untreated and siRNA-treated (scrambled or combined siRNAs 1 23) HEK-G11 cells with the pEGFP-CaSR
construct. Bar indicates 50 m. D and E, Ca2i response to changes in [Ca
2]o of FHH2-associated mutant Gln-135 HEK-G11 cells following siRNA knockdown of
endogenousWTG11. TheCa
2
i responses tochanges in [Ca
2]oareexpressedasapercentageof themaximumnormalizedresponsesandshownas themeanS.E.
of 4–5 independent transfections (i.e.biological replicates). The FHH2-associatedG11mutant (Gln-135) led to a rightward shift of the concentration-response curve
(blue),withasignificant increase inEC50valuecomparedwithWTG11 (inD,black;and inE,openbar). Theadditionof10nMcinacalcet (Cin)normalized theEC50values
ofcells in thepresenceofscrambled(gray)orGNA11-targetedsiRNAs (siRNAs123) (red).FandG,Ca2i responsetochanges in [Ca
2]oofADH2-associatedmutant
Gln-181HEK-G11 cells followingsiRNAknockdownofendogenousWTG11. TheADH2-associatedG11mutant (Gln-181) led toa leftwardshiftof theconcentration-
response curve (blue), with a significant decrease in EC50 value compared with WT G11 (in F, black; and in G, open bar). The addition of 10 nM NPS-2143 (2143)
normalized the EC50 value of cells in the presence of scrambled (gray) orGNA11-targeted siRNAs (siRNAs 1 23) (red). ***, p 0.0001;, nil; scram, scrambled.
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Gln-181 G11 mutant protein, the addition of 20 nMNPS 2143 to
cells expressing the Leu-341 G11 mutant did not significantly
alter theEC50. (Fig. 2E). Indeed,NPS-2143at a concentrationof 30
nM was required to increase the Leu-341 mutant EC50 value to
2.66 0.09mM and rectify the shift in themutant concentration-
response curve (Fig. 2, E andG).
Effect of CaSR Allosteric Modulators on the Ca2i Responses
in Absence of Endogenously Expressed WT G11 Protein—To
determine whether CaSR-targeted drugs rectify the Ca2i
responses of FHH2- and ADH2-mutant expressing cells by
directly influencing mutant G11-signaling or by indirect
effects on WT G11 protein that is endogenously expressed in
HEK293 cells, siRNA knockdown of endogenousWTG11 was
undertaken in HEK-G11 cells stably expressing WT, FHH2-
associatedGln-135, or ADH2-associatedGln-181mutant G11
proteins. Western blot analysis demonstrated that siRNA with
a scrambled sequence did not alter endogenous WT G11
expression in untransfectedHEK293 cells (Fig. 3A). In contrast,
GNA11-targeted siRNA reduced endogenous WT G11
expression in untransfected HEK293 cells (Fig. 3A), and
decreased the level of transiently expressed WT G11 in
HEK293 cells (Fig. 3B), but did not affect the levels of stably
expressedWTormutantG11 proteins inHEK-G11 cells (Fig.
3B), which contained constructs with silent mutations that had
rendered them resistant toGNA11-targeted siRNA. CaSR con-
structs were transiently transfected into HEK-G11 cells, and
CaSR expression confirmed by fluorescence microscopy (Fig.
3C). The effects of cinacalcet or NPS-2143 on the Ca2i
responses of the FHH2- and ADH2-associated G11 mutants
were assessed following knockdown of endogenous WT G11
using GNA11-targeted siRNAs (Fig. 3, D–G). These studies
revealed that: 10 nM of cinacalcet could rectify the rightward
shift in the concentration-response curve and lower the signif-
icantly raised EC50 of the FHH2-associated Gln-135 G11
mutant from a value of 3.85 0.12 mM to values of 3.23 0.1
mM and 3.17  0.08 mM, respectively, in the presence of
GNA11-targeted or scrambled siRNA (Fig. 3, D and E), so that
these values were not significantly different from HEK-G11
cells stably expressingWTG11 (EC50 3.33 0.06 mM); and
that 10 nM of NPS-2143 could normalize the leftward shift of
the concentration-response curve and increased the EC50 of the
ADH2-associated Gln-181 G11 mutant from a value of 2.70
0.07 mM to values of 3.26  0.06 mM and 3.11  0.08 mM,
respectively, in the presence of GNA11-targeted or scrambled
siRNA (Fig. 3, F and G), so that these values were not signifi-
cantly different from WT-expressing HEK-G11 cells. Thus,
these results show that CaSR-targeted drugs can influence the
signaling responses of downstream mutant G11 proteins.
Effect of ADH2-associated G11 Mutants on MAPK
Signaling—To investigate whether the germline R181Q and
F341L ADH2-associated mutant G11 proteins may lead to
constitutive up-regulation ofMAPK signaling,WT andmutant
GNA11-pBI-CMV2 vectors were transiently transfected into
HEK-CaSR cells and fold-change ERK phosphorylation (phos-
pho-ERK) responses assessed following exposure to varying
[Ca2]o. The effects of the ADH2-associated mutants on phos-
pho-ERK responses were compared with the uveal melanoma-
associated Q209L G11 mutation (11). Following stimulation
with Ca2o, the germline Gln-181 and Leu-341 mutants were
revealed to have significantly (p  0.001) increased maximal
phospho-ERK fold-change responses (Gln-181  18.1  1.1,
Leu-341  18.3  0.9) compared with WT G11 (14.7  0.3),
consistent with a gain-of-function (Fig. 4A). However, in the
absence of Ca2o stimulation, the basal phospho-ERK
responses of the ADH2mutants were demonstrated to not dif-
fer fromWTG11 (Fig. 4,A and B), and thus these mutants are
not constitutively activating. In contrast, the tumor-associated
somatic Q209L G11 mutation led to both significantly (p 
0.0001) increased basal and maximal phospho-ERK fold-
change responses when compared with the ADH2 mutants or
WT G11, consistent with a constitutive up-regulation of
MAPK signaling (Fig. 4,A and B). The effect of NPS-2143 on the
phospho-ERK responses of HEK-CaSR cells expressing the
ADH2-associated Gln-181 or Leu-341mutants, or the uveal mel-
anoma-associated Leu-209 mutant, was also assessed. NPS-2143
was added at 10 and 30 nM concentrations to cells expressing the
Gln-181 and Leu-341 mutants, respectively, as these doses had
rectified theCa2i responses of theG11mutants (Fig. 2,F andG).
The addition of 10 and 30 nMNPS-2143 significantly lowered the
maximal fold-change responses of the Gln-181 and Leu-341
mutants to 14.0  0.5 and 14.9  0.4, respectively, so that these
values did not differ from the phospho-ERK responses of cells
expressingWT G11 (Fig. 4, C and D). However, cells expressing
the uveal melanoma-associated Leu-209 mutant required NPS-
2143 at a higher dose of 500 nM to successfully rectify increases in
phospho-ERK responses (Fig. 4E).
Discussion
Our studies demonstrate that cinacalcet and NPS-2143, which
are allosteric CaSR activators and inactivators, respectively, can
successfully rectify the loss-of-function associated with FHH2-
causing G11 mutations and the gain-of-function associated with
G11 mutations that lead to ADH2 or uveal melanomas (1, 11).
Cinacalcet and NPS-2143 are allosteric modulators that are pre-
dicted to bind to theCaSR transmembrane domain (24) and influ-
ence receptor activity by altering its conformational status. These
compounds have been reported to rectify the activity of FHH1-
and ADH1-associated mutant CaSR proteins in vitro (15, 25–27).
However, the ability of these agents to normalize CaSR sensitivity
in the presence of an abnormality downstream of the CaSR
remained unknown. The in vitro findings of our study indicate
allosteric modulation at the level of the receptor can rectify such
loss- and gain-of-function associated with mutations of the intra-
cellular G11 protein. Indeed, these studies demonstrate that
pharmacological GPCR modulation may directly overcome
abnormalities affecting the downstream effector G-protein rather
than by indirect effects on endogenously expressed WT
G-proteins.
However, the G11 mutations showed differences in their
responsiveness to allosteric CaSR modulators. For example, our
study of the FHH2 mutants revealed that a 4-fold increase in the
cinacalcet dose was required to normalize the loss-of-function
associated with I199/200del compared withthe L135Q mutation,
despite both mutations having similar EC50 values. Similarly, a
3-fold increase in theNPS-2143 dosagewas required to rectify the
gain-of-function due to the ADH2-associated F341L mutation
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FIGURE4.Phospho-ERKresponsesofG11mutationsassociatedwithADH2oruvealmelanoma.A, phospho-ERK response tochanges in [Ca
2]owasmeasured
byquantitative immunoassay (Alphascreen) inHEK-CaSR cells transiently transfectedwithWTorADH2-associatedG11mutants (Gln-181 and Leu-341), or the uveal
melanoma (UV)-associated Leu-209G11mutant protein. Phospho-ERK responses at each [Ca
2]o are expressed as a fold-change of the response of cells stimulated
with basal (0.5 mM) [Ca2]o, and are shown as the mean S.E. of 9–24 assays from 3–8 independent transfections. The uveal melanoma-associated Leu-209 G11
mutant isassociatedwithsignificantly increasedmaximalphospho-ERKfold-changeresponsescomparedwithWT(Gln-209)andtheADH2mutantG11proteins.The
Gln-181andLeu-341mutantsalso inducedsignificant increases inmaximalphospho-ERKfold-changeresponsescomparedwithWTG11,whichharborsArgandPhe
residues at codons 181 and341, respectively.B, quantificationof thebasal phospho-ERK responses shown inA. Values are expressed as a percentageof theWTbasal
phospho-ERK response. The uvealmelanoma-associated Leu-209 G11mutant induces a significant phospho-ERK elevationwhen exposed to basal 0.5mM [Ca
2]o,
whereas the basal phospho-ERK responses of the ADH2-associated G11 mutants are not significantly different comparedwithWTG11. C–E, addition of NPS-2143
(2143) at 10, 30, and 500nM concentrations significantly decreased thephospho-ERK responses of theADH2-associatedGln-181 and Leu-341G11mutants, and the
UV-associated Leu-209mutant G11 protein, respectively, to values that were not significantly different fromWTG11. ***, p 0.0001.
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when compared with the gain-of-function R181Q mutation,
despitebothmutationshaving similarEC50 values.Thus, the I199/
200del and F341L mutations showed diminished sensitivity to
cinacalcet andNPS-2143, respectively, and thesedifferences in the
sensitivities of the mutants to CaSR-targeted drugs may be
explained by a reported crystallography study, which showed res-
idues homologous to Ile-199 and Phe-341, in the related Gs pro-
tein to be located at the interface between GPCR andG-subunit
(28).Thus,G11mutations locatedat theGPCR-G interfacemay
potentially influence the efficacy of CaSR allosteric modulators.
Cells expressing loss- and gain-of-function G11 mutants
responded to nanomolar concentrations of cinacalcet (10–40 nM,
which is equivalent to 3.6–14.3 ng/ml) andNPS-2143 (10–30 nM,
which is equivalent to 4.4–13.3 ng/ml), respectively. However,
previous in vitro studies of CaSR mutations leading to FHH and
ADH have indicated that micromolar concentrations of these
drugs may be required to rectify associated signal transduction
abnormalities (25–27), and in vivo studies in WT rats have
reported that the plasma drug concentrations of cinacalcet and
NPS-2143 required to alter PTH secretion are 20 ng/ml and
100 ng/ml, respectively (29, 30). The responsiveness of G11
mutants to lowdoses of CaSR-targeted drugsmay be explained by
the finding that thesemutants inducedonlyminordisturbances of
CaSR signal transduction. Indeed, the FHH2 and ADH2mutants
were associated with up to a 30% shift in the EC50 values of HEK-
CaSR cells used in this study, whereas CaSRmutations leading to
FHH1andADH1generallycausea50%shift in theEC50value (9,
21, 31, 32).However, it remains tobeestablishedwhether such low
concentrations of calcimimetic and calcilytic drugs will be able to
rectify in vivo the alterations inmineral homeostasis in FHH2 and
ADH2 patients.
Somatic gain-of-function G11 mutations that induce con-
stitutive MAPK activation have been reported in uveal mela-
noma and are associated with an increased likelihood of metas-
tases (11). We therefore assessed the effects of germline ADH2-
associatedR181Qand F341L gain-of-functionG11mutations on
MAPK signaling by measuring phospho-ERK responses. Our
studies demonstrated that the ADH2 G11 mutants induced a
milder increase in ERKphosphorylationwhen comparedwith the
uvealmelanomaQ209LG11mutant.Moreover, up-regulationof
ERKphosphorylationby theADH2-associatedG11mutants only
occurred in thepresenceofCa2o stimulation, and therefore these
R181Q and F341LG11mutants do not harbor constitutive activ-
ity.These findings are consistentwith a recent report of anADH2-
associated R60L G11 mutation, which also enhanced MAPK
activation in a non-constitutive manner (7). The finding that
ADH2-associated mutations are not constitutively activating can
be explained by their locations within the GTPase domain of the
G subunit. Thus, the Gln-209 residue, which is mutated in uveal
melanomas (11), is required to spatially orientate the terminal
phosphate group of G-bound GTP (33), thereby facilitating its
hydrolysis and theconversionofGTPtoGDP.Mutationsaffecting
the Gln-209 residue have been shown to abolish GTP hydrolysis,
thereby leaving the G subunit in a permanent GTP-bound state
of activation (34). In contrast, the Arg-181 and Phe-341 G11 res-
idues, which are mutated in ADH2, are not located near to the
terminal phosphate of GTP, and likely induce more indirect and
subtle effects on GTP hydrolysis (1). The ADH2-associated G11
mutations represent the first reports of non-constitutively activat-
ing G-protein mutations (1, 6, 7), and the milder nature of these
mutations is consistent with post-natal survival, in contrast to the
constitutively activating Q209L mutation, which has been shown
tobecytotoxicwhenexpressedathigh levels (35), and is likely tobe
embryonically lethal. The occurrence of non-constitutively acti-
vatingG11mutations that are tolerated in humans and heritable,
highlights thepotential for suchgermlinemutations toaffectother
G-proteinsandbeassociatedwithdisease-relatedphenotypes, and
this possibility remains to be explored.
In summary, our studies have revealed that germline gain-of-
function G11 mutations induce non-constitutive alterations in
MAPK signaling, and that CaSR-targeted compoundsmay rectify
signaling disturbances caused by germline and somatic G11
mutations, which are associated with calcium disorders and
tumorigenesis, respectively. These findings indicate that allosteric
modulation at the level of the receptor may influence signaling
disturbances associated with mutations of the downstream
G-protein.
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